Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment

NCT01723670 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: CHF 5074 1x
DRUG: CHF 5074 2x
DRUG: Placebo

Sponsor

CERESPIR